Compare ALEMBIC with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs NOVARTIS - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC NOVARTIS ALEMBIC/
NOVARTIS
 
P/E (TTM) x 61.2 1,943.4 3.1% View Chart
P/BV x 5.3 25.8 20.4% View Chart
Dividend Yield % 0.2 1.7 11.3%  

Financials

 ALEMBIC   NOVARTIS
EQUITY SHARE DATA
    ALEMBIC
Mar-18
NOVARTIS
Mar-19
ALEMBIC/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs72980 7.3%   
Low Rs34600 5.6%   
Sales per share (Unadj.) Rs4.7198.7 2.4%  
Earnings per share (Unadj.) Rs6.121.0 29.1%  
Cash flow per share (Unadj.) Rs6.222.3 28.1%  
Dividends per share (Unadj.) Rs0.2010.00 2.0%  
Dividend yield (eoy) %0.41.3 29.8%  
Book value per share (Unadj.) Rs40.7307.5 13.2%  
Shares outstanding (eoy) m267.0324.69 1,081.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.34.0 283.3%   
Avg P/E ratio x8.737.7 23.0%  
P/CF ratio (eoy) x8.535.5 23.9%  
Price / Book Value ratio x1.32.6 50.7%  
Dividend payout %3.347.7 6.9%   
Avg Mkt Cap Rs m14,13919,508 72.5%   
No. of employees `000NA0.6 0.0%   
Total wages/salary Rs m2071,171 17.7%   
Avg. sales/employee Rs ThNM8,445.4-  
Avg. wages/employee Rs ThNM2,015.7-  
Avg. net profit/employee Rs ThNM891.0-  
INCOME DATA
Net Sales Rs m1,2554,907 25.6%  
Other income Rs m370783 47.3%   
Total revenues Rs m1,6255,689 28.6%   
Gross profit Rs m111123 90.5%  
Depreciation Rs m3832 118.9%   
Interest Rs m216 10.7%   
Profit before tax Rs m442858 51.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24340 7.0%   
Profit after tax Rs m1,630518 314.8%  
Gross profit margin %8.92.5 353.7%  
Effective tax rate %5.439.6 13.7%   
Net profit margin %129.810.6 1,230.7%  
BALANCE SHEET DATA
Current assets Rs m1,8678,055 23.2%   
Current liabilities Rs m5911,850 32.0%   
Net working cap to sales %101.6126.4 80.4%  
Current ratio x3.24.4 72.5%  
Inventory Days Days9445 209.4%  
Debtors Days Days7434 216.9%  
Net fixed assets Rs m1,791150 1,195.5%   
Share capital Rs m534123 432.8%   
"Free" reserves Rs m10,3247,469 138.2%   
Net worth Rs m10,8587,592 143.0%   
Long term debt Rs m410-   
Total assets Rs m11,5919,824 118.0%  
Interest coverage x260.954.9 474.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.5 21.7%   
Return on assets %14.15.4 259.2%  
Return on equity %15.06.8 220.1%  
Return on capital %15.211.5 132.0%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1958 33.7%   
Fx outflow Rs m2641,326 19.9%   
Net fx Rs m-244-1,269 19.3%   
CASH FLOW
From Operations Rs m236-1,943 -12.1%  
From Investments Rs m-2242,742 -8.2%  
From Financial Activity Rs m-27-298 8.9%  
Net Cashflow Rs m-15501 -3.0%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 2.0 10.0%  
FIIs % 9.7 1.6 606.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 21.5 121.4%  
Shareholders   54,701 41,647 131.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   IPCA LABS  GSK PHARMA  PANACEA BIOTECH  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare ALEMBIC With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Apr 16, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS